Silence Therapeutics plc SLN

Latest FY: 2025 Healthcare Biotechnology
Market Price $13.74
Market Cap $660.81M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↓-98.7% YoY
$559.00K
3-Yr CAGR: -68.3%
Net Income ↓-95.6% YoY
-$88.61M
Net Margin: -15,851.9%
Free Cash Flow ↑8.1% YoY
-$62.33M
FCF Yield: -9.43%
EPS (Diluted) ↓-90.9% YoY
$-0.63
Basic: $-0.63
Return on Equity Efficiency
-142.2%
ROA: -67.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (SLN)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2019 $0.2M $0.1M $-22.9M $1.7M $1.7M
FY 2020 $5.5M +2,145.5% $1.7M $-36.0M -57.6% $-10.8M $-11.3M -757.0%
FY 2021 $12.4M +126.6% $5.0M $-45.9M -27.2% $6.8M $5.5M +148.7%
FY 2022 $17.5M +41.0% $6.6M $-47.4M -3.3% $-45.5M $-45.6M -929.8%
FY 2023 $25.4M +45.0% $15.1M $-50.3M -6.2% $-39.4M $-39.4M +13.6%
FY 2024 $43.3M +70.5% $31.4M $-45.3M +9.9% $-0.33 $-67.6M $-67.9M -72.2%
FY 2025 $0.6M -98.7% $0.3M $-88.6M -95.6% $-0.63 -90.9% $-62.3M $-62.3M +8.1%
$

Valuation

Market Price $13.74
Market Cap $660.81M
Enterprise Value $649.77M
P/E Ratio N/A
P/B Ratio 10.42
FCF Yield -9.43%
Dividend Yield N/A
Shares Outstanding 47,234,613
%

Profitability & Margins

Gross Margin 61.54%
Operating Margin -16,292.84%
Net Margin -15,851.88%
Return on Equity (ROE) -142.23%
Return on Assets (ROA) -67.42%
Asset Turnover 0.00x
Revenue 3-Yr CAGR -68.27%
🛡️

Financial Health & Liquidity

Current Ratio 8.72
Cash Ratio 0.83
Debt / Equity 0.004
Debt / Assets 0.002
Cash & Equivalents $11.28M
Total Debt $231.00K
Book Value / Share $1.32
💧

Cash Flow Efficiency

Operating Cash Flow -$62.27M
Capital Expenditures (CapEx) $55.00K
Free Cash Flow -$62.33M
OCF / Revenue -11,139.71%
FCF / Revenue -11,149.55%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.63
EPS (Basic) $-0.63
Dividends / Share N/A
Book Value / Share $1.32
EPS YoY Growth -90.91%
🏛️

Balance Sheet (FY 2025)

Total Assets $131.44M
Total Liabilities $69.14M
Stockholders' Equity $62.30M
Current Assets $118.66M
Current Liabilities $13.61M